MCID: BLD039
MIFTS: 34

Bladder Adenocarcinoma malady

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

About this section

Aliases & Descriptions for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 11 13 68
Bladder Adenocarcinoma, Not Otherwise Specified 11
Adenocarcinoma of the Urinary Bladder 11
 
Adenocarcinoma of Bladder 11
Adenocarcinoma Bladder 50

Classifications:



External Ids:

Disease Ontology11 DOID:3711
SNOMED-CT62 255110003

Summaries for Bladder Adenocarcinoma

About this section
Disease Ontology:11 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to pelvic lipomatosis and bladder clear cell adenocarcinoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is CDX2 (Caudal Type Homeobox 2). Affiliated tissues include prostate, kidney and liver.

Related Diseases for Bladder Adenocarcinoma

About this section

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 69)
idRelated DiseaseScoreTop Affiliating Genes
1pelvic lipomatosis11.0
2bladder clear cell adenocarcinoma10.9
3bladder signet ring cell adenocarcinoma10.9
4malignant biphasic mesothelioma10.3GATA3, PCNA
5adenocarcinoma10.3
6desmoplastic infantile astrocytoma10.2MKI67, PCNA
7novak syndrome10.1CDX2, MKI67
8sensory system cancer10.1CDX2, KRT20
9pulmonary neuroendocrine tumor10.1CDX2, KRT20
10cellular phase chronic idiopathic myelofibrosis10.1CDX2, KRT20
11iris disease10.1CDX2, KRT20
12ovarian melanoma10.1CDX2, KRT20
13appendix adenocarcinoma10.1CDX2, KRT20
14klatskin's tumor10.1CDX2, KRT20
15appendix lymphoma10.1CDX2, KRT20
16chronic eustachian salpingitis10.1CDX2, KRT20
17benign mesenchymoma10.1CDX2, KRT20
18tabes dorsalis10.1CDX2, KRT20
19prostate signet ring cell adenocarcinoma10.1CDX2, KRT20
20spastic ataxia 310.1CDX2, KRT20
21migraine with aura10.1CDX2, KRT20
22ovarian serous adenofibroma10.1CDX2, KRT20
23hypoparathyroidism-intellectual disability-dysmorphism syndrome10.1CDX2, KRT20
24food allergy10.1CDX2, KRT20
25pediatric testicular germ cell tumor10.1CDX2, KRT20
26lateral sinus thrombosis10.0CDX2, KRT20
27extrahepatic bile duct adenocarcinoma10.0CDX2, KRT20
28pyoderma10.0GATA3, KRT20
29striated muscle rhabdoid tumor10.0CDX2, KRT20
30bladder calculus10.0CDX2, KRT20
31cervix endometriosis10.0CDX2, KRT20
32pediatric meningioma10.0CDX2, KRT20
33mesenchymoma10.0CDX2, KRT20
34sclerosing hemangioma10.0CDX2, KRT20
35breast scirrhous carcinoma10.0CDX2, KRT20
36optic papillitis10.0CDX2, KRT20
37gastrointestinal neuroendocrine tumor10.0CDX2, KRT20
38submucosal invasive colon adenocarcinoma9.9CDX2, KRT20
39fallopian tube mucinous adenocarcinoma9.9CDX2, KRT20
40prolapse of lacrimal gland9.9KLK3, PCNA
41postgastrectomy syndrome9.9CDX2, KRT20
42sphenoid sinus squamous cell carcinoma9.9KLK3, KRT20
43neurodermatitis9.9CDX2, KRT20
44colon mucinous adenocarcinoma9.8KLK3, KRT20
45sphenoidal sinus cancer9.8KLK3, KRT20
46localized pulmonary fibrosis9.8KLK3, KRT20
47peritoneal serous adenocarcinoma9.8CDX2, KRT20
48ectodermal dysplasia with natal teeth, turnpenny type9.8CDX2, KRT20
49exstrophy of the bladder9.8
50nerve fibre bundle defect9.7KLK3, KRT20

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to bladder adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

About this section

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

Drugs & Therapeutics for Bladder Adenocarcinoma

About this section

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 191)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
NicotineapprovedPhase 4105054-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
2
FesoterodineapprovedPhase 460286930-02-7, 286930-03-86918558
Synonyms:
FESO
 
Fesoterodine
Toviaz
3Cholinergic AgentsPhase 43846
4Nicotinic AgonistsPhase 4902
5Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 222776
6Central Nervous System StimulantsPhase 4, Phase 1, Phase 22132
7Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13868
8Cholinergic AntagonistsPhase 41658
9Neurotransmitter AgentsPhase 4, Phase 217734
10Muscarinic AntagonistsPhase 41134
11Autonomic AgentsPhase 49774
12
GemcitabineapprovedPhase 3, Phase 2, Phase 1197495058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
13
EpirubicinapprovedPhase 338356420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
14
Capecitabineapproved, investigationalPhase 3, Phase 21296154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
15
Oxaliplatinapproved, investigationalPhase 3, Phase 1141261825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
16
CisplatinapprovedPhase 3, Phase 2269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
17
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
18
FluorouracilapprovedPhase 3, Phase 2, Phase 1179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
19VaccinesPhase 3, Phase 1, Phase 26428
20AntimetabolitesPhase 3, Phase 2, Phase 111774
21Topoisomerase InhibitorsPhase 3, Phase 2, Phase 14945
22Immunosuppressive AgentsPhase 3, Phase 2, Phase 112770
23Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17171
24Nucleic Acid Synthesis InhibitorsPhase 3, Phase 24855
25Adjuvants, ImmunologicPhase 3, Phase 2, Phase 12484
26Antibiotics, AntitubercularPhase 3, Phase 2, Phase 16972
27Pharmaceutical SolutionsPhase 3, Phase 1, Phase 27793
28Alkylating AgentsPhase 3, Phase 24694
29Anti-Bacterial AgentsPhase 3, Phase 2, Phase 110884
30Antiviral AgentsPhase 3, Phase 2, Phase 19732
31Anti-Infective AgentsPhase 3, Phase 2, Phase 121402
32MitomycinsPhase 3, Phase 2233
33Interferon-alphaPhase 31139
34interferonsPhase 3, Phase 1, Phase 22137
35BCG VaccinePhase 3103
36AndrogensPhase 3, Phase 1, Phase 21275
37NarcoticsPhase 33486
38pancreatic polypeptidePhase 3, Phase 120
39Central Nervous System DepressantsPhase 312806
40AnalgesicsPhase 3, Phase 211287
41Adjuvants, AnesthesiaPhase 31588
42Analgesics, OpioidPhase 33091
43AnestheticsPhase 39001
44Anesthetics, IntravenousPhase 32406
45Anesthetics, GeneralPhase 32787
46HormonesPhase 3, Phase 1, Phase 213979
47Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 312767
48Hormone AntagonistsPhase 312778
49ColaNutraceuticalPhase 3, Phase 1, Phase 21881
50
EtoposideapprovedPhase 2123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide

Interventional clinical trials:

(show top 50)    (show all 124)
idNameStatusNCT IDPhase
1A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic ProstatectomyCompletedNCT01661166Phase 4
2Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
3Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder CancerUnknown statusNCT01094964Phase 3
4Randomized Trial on Robotic Assisted Resection for Rectal CancerUnknown statusNCT01130233Phase 3
5Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract CarcinomaUnknown statusNCT01470443Phase 3
6Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder CancerCompletedNCT00024349Phase 3
7Image Guided Radiation Therapy For Prostate CancerCompletedNCT00433706Phase 3
8Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
9Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract CancerRecruitingNCT02170090Phase 3
10Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer PatientsRecruitingNCT02303327Phase 3
11Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the ProstateActive, not recruitingNCT01444820Phase 3
12Radiotherapy - Adjuvant Versus Early SalvageActive, not recruitingNCT00860652Phase 3
13Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder CancerUnknown statusNCT01196403Phase 2
14A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular CarcinomaUnknown statusNCT00183885Phase 2
15VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumCompletedNCT00407485Phase 2
16Piritrexim in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00002914Phase 2
17Combination Chemotherapy in Patients With Advanced Urinary Tract CancerCompletedNCT00002684Phase 2
18Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary TractCompletedNCT00006026Phase 2
19A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile DuctsCompletedNCT01007552Phase 2
20Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic AdenocarcinomasCompletedNCT02487836Phase 2
21Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate AdenocarcinomaCompletedNCT00252941Phase 1, Phase 2
22Triapine and Gemcitabine Hydrochloride in Gallbladder CancerCompletedNCT00075504Phase 2
23Radiation Therapy in Treating Patients With Stage II or Stage III Prostate CancerCompletedNCT00002602Phase 1, Phase 2
24Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During SurgeryCompletedNCT00003744Phase 2
25Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCompletedNCT00633789Phase 2
26High-dose ICE With AmifostineCompletedNCT00003657Phase 2
27Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1, Phase 2
28Bupropion in Helping Adults Stop SmokingCompletedNCT00534001Phase 2
29Zinc Supplements in Lowering Cadmium Levels in SmokersCompletedNCT00376987Phase 2
30A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1CompletedNCT00948961Phase 1, Phase 2
31Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
32Study of Tremelimumab in Patients With Advanced Solid TumorsRecruitingNCT02527434Phase 2
33A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT01928394Phase 1, Phase 2
34A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsRecruitingNCT02452424Phase 1, Phase 2
35Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the UrotheliumRecruitingNCT00756639Phase 2
36Phase I/II Study of IMMU-132 in Patients With Epithelial CancersRecruitingNCT01631552Phase 1, Phase 2
37Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney CancersRecruitingNCT02141490Phase 2
38A Phase II Study to Evaluate the Efficacy, and Safety of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) or Pancreas/Cholangio Cancer (KamelRecruitingNCT02999672Phase 2
39Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06RecruitingNCT01164150Phase 2
40A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid TumorsRecruitingNCT02886897Phase 1, Phase 2
41Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced CholangiocarcinomaRecruitingNCT02631590Phase 2
42Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsRecruitingNCT02646319Phase 2
43A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerRecruitingNCT02543645Phase 1, Phase 2
44Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
45Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal RemnantActive, not recruitingNCT00082706Phase 2
46Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate CancersActive, not recruitingNCT01148069Phase 2
47Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate CancerActive, not recruitingNCT02031328Phase 1, Phase 2
48Proton Therapy for Low and Intermediate Risk Prostate CancerActive, not recruitingNCT00693238Phase 2
49Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate CancerActive, not recruitingNCT01368055Phase 2
50Cabozantinib for Advanced Urothelial CancerActive, not recruitingNCT01688999Phase 2

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

About this section

Anatomical Context for Bladder Adenocarcinoma

About this section

MalaCards organs/tissues related to Bladder Adenocarcinoma:

36
Prostate, Kidney, Liver, Lung, Colon, Testes, Endothelial

Publications for Bladder Adenocarcinoma

About this section

Articles related to Bladder Adenocarcinoma:

(show all 32)
idTitleAuthorsYear
1
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. (27288750)
2016
2
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. (27006847)
2016
3
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. (26955660)
2016
4
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. (27427223)
2016
5
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. (27048257)
2016
6
Gall bladder Adenocarcinoma in a Young Girl. (26139973)
2015
7
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. (26421206)
2015
8
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. (25040620)
2014
9
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. (24716732)
2014
10
Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. (23589601)
2013
11
Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen. (24281125)
2013
12
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. (24596525)
2013
13
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. (23076693)
2012
14
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. (22804747)
2012
15
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. (23121893)
2012
16
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. (22081531)
2011
17
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. (22294067)
2011
18
Bladder adenocarcinoma following gastrocystoplasty. (20392671)
2010
19
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. (19221283)
2009
20
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. (18307003)
2008
21
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. (18604226)
2008
22
Urinary bladder adenocarcinoma arising in a spina bifida patient. (18022132)
2007
23
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. (15822823)
2005
24
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. (19861819)
2003
25
Spontaneous resolution of bladder adenocarcinoma. (15160537)
2003
26
Bladder adenocarcinoma: 31 reported cases. (11718635)
2001
27
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. (11506474)
2001
28
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. (10510893)
1999
29
Urine cytology of primary and secondary urinary bladder adenocarcinoma. (9915134)
1998
30
Bladder adenocarcinoma during pregnancy: a case report. (8855078)
1996
31
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. (8389497)
1993
32
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). (6983292)
1982

Variations for Bladder Adenocarcinoma

About this section

Expression for genes affiliated with Bladder Adenocarcinoma

About this section
Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for genes affiliated with Bladder Adenocarcinoma

About this section

GO Terms for genes affiliated with Bladder Adenocarcinoma

About this section

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1animal organ morphogenesisGO:000988710.0CDX2, GATA3
2positive regulation of cell differentiationGO:00455979.5CDX2, GATA3

Sources for Bladder Adenocarcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet